JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Momentum-inputs (vergelijkbare managers):
breedte van houders +15.0% ·
aandelenstroom -0.5% ·
netto nieuwe posities +13.0%
· formule
Fragmentatie van eigendom: meer houders, kleiner totaalbelang
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 12.70M | $3.29B | n/a | −1 |
| Q2 2026 | 181 | +1 | 1.42B | $361.32B | +5 | −5 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | n/a | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | n/a |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | n/a | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | n/a |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | n/a | −2 |
| Q2 2024 | 21 | n/a | 161.11M | $23.53B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 134.46M | n/a | $19.44B | 0.8% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 57.67M | +2.8% | $8.32B | 0.6% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passief) | 30.36M | +4.5% | $4.39B | 0.6% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 24.36M | +1.8% | $3.52B | 0.6% | ▲ Add | 3 | SEC ↗ ×7 |
| 5 | T. Rowe Price ✦ | 16.28M | -35.3% | $2.35B | 0.3% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | Fisher Asset Management ✦ | 8.19M | +8.4% | $1.19B | 0.5% | ▲ Add | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 4.06M | -23.0% | $586.83M | 0.7% | ▼ Trim | 3 | SEC ↗ ×3 |
| 8 | AQR Capital Management ✦ | 3.47M | +9.9% | $500.09M | 0.6% | ▲ Add | 3 | SEC ↗ ×6 |
| 9 | Arrowstreet Capital ✦ | 2.37M | +105.3% | $342.27M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.87M | +183.6% | $269.75M | 0.3% | ▲ Add | 3 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 1.75M | +2046.0% | $252.54M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 12 | Tweedy, Browne ✦ | 1.08M | -4.1% | $156.26M | 10.5% | ▼ Trim | 3 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 972.01K | +375.6% | $140.57M | 0.2% | ▲ Add | 3 | SEC ↗ ×2 |
| 14 | Adage Capital Partners ✦ | 934.80K | -42.3% | $135.19M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 921.50K | Nieuw | $133.27M | 0.2% | New | 1 | SEC ↗ |
| 16 | Markel Group ✦ | 610.80K | 0.0% | $88.33M | 0.8% | Held | 3 | SEC ↗ ×2 |
| 17 | Bridgewater Associates ✦ | 537.94K | -63.4% | $77.80M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 305.73K | Nieuw | $44.21M | 0.1% | New | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 199.13K | -8.5% | $28.80M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 20 | GAMCO Investors ✦ | 92.93K | -3.8% | $13.44M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 21 | Fairfax Financial ✦ | 73.40K | 0.0% | $10.62M | 0.7% | Held | 3 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 63.77K | Nieuw | $9.22M | 0.0% | New | 1 | SEC ↗ |
| 23 | Dodge & Cox ✦ | 21.10K | 0.0% | $3.05M | 0.0% | Held | 3 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Renaissance Technologies | $133.27M | 0.2% |
| Point72 Asset Management | $44.21M | 0.1% |
| Two Sigma Investments | $9.22M | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 136.10K aandelen, $33,268 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 11.07K aand · $3.04M
Officer · 22.53K aand · $6.19M
Officer · 15.00K aand · $3.95M
Officer, Director · 102.31K aand · $26.70M
Officer, Director · 20.98K aand · $5.50M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie